PVLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Palvella Therapeutics (PVLA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, positive catalysts from clinical trial results, and a promising pipeline for orphan skin diseases. While the financials show losses, the company is in a growth phase with significant upside potential.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 51.565, and moving averages are converging, suggesting consolidation. The pre-market price of $83.66 is near the resistance level (R1: $83.894), indicating potential for a breakout.
Positive Phase 2 clinical trial results for Qtorin rapamycin in cutaneous venous malformations, with 73% of patients showing improvement.
Multiple analysts have raised price targets significantly, with targets ranging from $174 to $
High conviction from analysts regarding FDA approval and expedited development timelines.
The company is not yet profitable, with a net income of -$11.35M in Q3
EPS dropped significantly YoY (-73.86%), reflecting financial challenges.
In Q3 2025, revenue remained at $0, indicating the company is in a pre-revenue phase. However, net income improved by 62.79% YoY, showing better cost management. EPS dropped to -1.03, reflecting ongoing losses.
Analysts are overwhelmingly positive, with multiple 'Buy' ratings and price targets raised significantly. The highest target is $212, reflecting strong confidence in the company's pipeline and growth potential.
